Nkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer cell therapies for cancer, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 4:30 p.m. ET. A webcast of the presentation will be available in the Investors section of Nkarta’s website and can be accessed after the live event for approximately four weeks. Nkarta specializes in developing off-the-shelf NK cell therapies designed for outpatient treatments, leveraging advanced cell engineering and cryopreservation technologies.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference:
21st Annual Needham Virtual Healthcare Conference
April 12, 2022
4:30 p.m. ET – presentation
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
What is Nkarta's participation in the 21st Annual Needham Virtual Healthcare Conference?
Where can I watch Nkarta's presentation from the healthcare conference?
How long will the replay of Nkarta's conference presentation be available?
What is the focus of Nkarta, Inc.?